Glatiramer acetate versus interferon beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients

Advances in Therapy

Volumn 25, Issue 7, 2008, Pages 658-673

  Castelli Haley, Jane ^a   Oleen Burkey, Merry Kay A ^a   Lage, Maureen J ^b   Johnson, Kenneth P ^c  

^a Teva Neuroscience   (United States)

^b HealthMetrics Outcomes Research LLC   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

Direct medical costs; Glatiramer acetate; Interferon beta 1a for subcutaneous administration; Multiple sclerosis; Relapse

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOLOGICAL ADJUVANT; PEPTIDE;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; COST; DRUG ADMINISTRATION; ECONOMICS; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; COHORT STUDIES; COSTS AND COST ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; PEPTIDES; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 58149357529     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-008-0077-z     Document Type: Article

References (54)

1. Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005;4:111-121. (Pubitemid 40138926)
2. Frohman EM. Multiple sclerosis. Med Clin North Am. 2003;87:867-897. (Pubitemid 36712843)
3. Multiple Sclerosis International Federation. Last updated 29 May 2007. Available at:www.msif.org/en/resources/msif-resources/msif-publications/ms-the- guide-to-treatment-and-management/foreword. html. Accessed 20 June 2007.
4. National Multiple Sclerosis Society. About MS: who gets MS? Last updated 12 August 2005. Available at: www.nationalmssociety. org/about-multiple- sclerosis/who-gets-ms/index.aspx. Accessed 1 July 2008.
5. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology. 2002;58:136-138. (Pubitemid 34041953)
6. Trapp BD, Peterson J, Ransohof RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278-285. (Pubitemid 28065253)
7. Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess. 2002;6:1-73.
8. Parkin D, Jacoby A, McNamee P, Miller P, Tomas S, Bates D. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-Effectiveness and quality of life. J Neurol Nerosurg Psychiatry. 2000;68:144-149. (Pubitemid 30245835)
9. Murphy N, Confavreux C, Haas J, et al. Quality of life in multiple sclerosis in France, Germany and the United Kingdom. Cost of Multiple Sclerosis Study Group. J Neurol Neurosurg Psychiatry. 1998;65:460-466. (Pubitemid 28438873)
10. Aronson KJ. Quality of life among persons with multiple sclerosis and their caregivers. Neurology. 1997;48:74-80. (Pubitemid 27039520)
11. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res. 1995;4:187-206.
12. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66:1696-1702. (Pubitemid 43964625)
13. Jackson M, Quaal C, Reeves MA. Effects of multiple sclerosis on occupational and career patterns. Axone. 1991;13:16-17, 20-22.
14. LaRocca NG, Kalb R, Scheinberg L, Kendall P. Factors associated with unemployment of patients with multiple sclerosis. J Chronic Dis. 1985;38:203-210. (Pubitemid 15141125)
15. LaRocca N, Kalb R, Gregg K. A program to facilitate retention of employment among persons with multiple sclerosis. Work. 1996;7:37-46. (Pubitemid 26173033)
16. Rumrill PD. Job placement and retention interventions. In: Rumrill PD Jr, ed. Employment Issues and Multiple Sclerosis. New York: Demos Vermande; 1996:65-88.
17. Agency for Healthcare Research and Quality. National Guideline Clearinghouse. Multiple sclerosis. National clinical guideline for diagnosis and management in primary and secondary care. Last modifed 1 October 2007 sic. Available at: www.guideline.gov/summary/summary.aspx?ss=15&doc-id= 5063&nbr=3547#s22. Accessed 4 October 2007.
18. Pohlman CH, Uitdehaag BM. Drug treatment of multiple sclerosis. BMJ. 2000;321:490-494. (Pubitemid 30623607)
19. Drugstore.com. Ask your pharmacist: what are the side of Effects of oral corticosteroids drugs? Last updated 15 March 2007. Available at: www.drugstore.com/pharmacy/ayp/questions.asp?label=1291&aypsearchstr= corticosteroid&pg=1&trx=8496&trxp1=1291. Accessed 1 July 2008.
20. Tullman MJ, Lublin FD, Miller AE. Immunotherapy of multiple sclerosis-current practice and future directions. J Rehabil Res Dev. 2002;39:273-285.
21. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efcacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56:1628-1636.
22. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomised, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol. 1999;46:197-206. (Pubitemid 29382876)
23. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498-1504.
24. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to defnite multiple sclerosis: a randomized study. Lancet. 2001;357:1576-1582. (Pubitemid 32488815)
25. ® Package Insert. Last updated February 2008. Available at: www.mslifelines.com/-assets/pdf/Rebif-PI.pdf. Accessed 1 July 2008.
26. National Multiple Sclerosis Society. National MS Society information sourcebook. Last updated October 2006. Available at: www.nationalmssociety.org/ about-multiple-sclerosis/treatments/medications/interferons/index.aspx. Accessed 1 July 2008.
27. Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifronis G, Wolinsky JS, Copaxone Study Group. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler. 2006;12:309-320. (Pubitemid 43827186)
28. Johnson KP, Brooks BR, Ford CC, et al. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler. 2003;9:585-591. (Pubitemid 37479407)
29. Johnson K P, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical Effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998;50:701-708.
30. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45:1268-1276.
31. Martinelli Boneschi F, Rovaris M, Johnson K P, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trails, Mult Scler. 2003;9:349-355. (Pubitemid 36958017)
32. Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology. 2000;54:813-817. (Pubitemid 30111334)
33. ® Prescribing Information. Last updated November 2007. Available at: www. Copaxone.com/pdf/PrescribingInformation. pdf. Accessed 1 July 2008.
34. Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin Pharmacother. 2001;2:1149-1165. (Pubitemid 32633717)
35. Davis WM. Multiple sclerosis: continuing mysteries and current management. Drug Topics. 2000. Available at: www.rxed. org/drugtopics/ce/2000/ ce061900.pdf. Accessed 23 June 2007.
36. Vallittu AM, Peltoniemi J, Elovaara I, et al. The efcacy of glatiramer acetate in beta-interferon-intolerant MS patients. Acta Neurol Scand. 2005;112:234-237. (Pubitemid 41337070)
37. Iskedjian MJ, Walker JH, Gray T, Vicente C, Einarson TR, Gehshan A. Economic evaluation of Avonex (interferon beta-1a) in patients following a single demyelinating event. Mult Scler. 2005;11:542-551. (Pubitemid 41387699)
38. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost-Effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health. 2004;7:554-568. (Pubitemid 39390836)
39. Kobelt G, Jönsson L, Fredrikson S. Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. Eur J Health Econ. 2003;4:50-59. (Pubitemid 36457057)
40. Phillips CJ. The cost of multiple sclerosis and the cost Effectiveness of disease-modifying agents in its treatment. Current Opinion. CNS Drugs. 2004;18:561-574. (Pubitemid 38951779)
41. Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost-Effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Phar. 2007;3:245-261. (Pubitemid 46730893)
42. Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8:469-476.
43. Woods SW, Baker CB. Cost-Effectiveness of the newer generation of antidepressants. In: Davis KL, Charney D, Coyle JT, Nemerof C, eds. Neuropsychopharmacology: The Fifh Generation of Progress. American College of Neuropsychopharmacology; 2002;1119-1137.
44. Croghan T W, Kniesner TJ, Melf CA, Robinson RL. Effect of antidepressant choice on the incidence and economic intensity of hospitalization among depressed individuals. Adm Policy Ment Health.2000;27:183-195. (Pubitemid 30432385)
45. Haas J. Open-label study to compare the clinical efcacy of immunomodulatory therapies (glatiramer acetate and interferons) in relapsing-remitting multiple sclerosis: four years of follow up. 15th Meeting of the European Neurological Society. 18-22 June 2005; Vienna, Austria.
46. Anderson JL, Ronnow BS, Horne BD, et al. Usefulness of a complete blood count-derived risk score to predict incident mortality in patients with suspected cardiovascular disease. Am J Cardiol. 2007;99:169-174. (Pubitemid 46072753)
47. Castrodale L, Beller M, Middaugh J, McCumber B, Mynes-Spink K, Bernth G. Use of liver function tests to predict the magnitude of an outbreak of hepatitis A. Clin Infect Dis. 2002;35:91-92. (Pubitemid 34666867)
48. Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm. 2007;13:44-52. (Pubitemid 46824250)
49. Calabresi PA. Considerations in the treatment of relapsing-remitting multiple sclerosis. Neurology. 2002;58:S10-S22. (Pubitemid 34411849)
50. Coyle PK, Christie S, Fodor P, et al. Multiple sclerosis gender issues: clinical practices of women neurologists. Mult Scler. 2004;5:582-588. (Pubitemid 39207234)
51. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefts of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler. 2000;6:255-266.
52. Li D, Abdalla JA. Long-term observational follow-up of the PRISMS cohort: analyses of MRI BOD shows beneft of high dose, high frequency IFN beta-1a (Rebif). Program and abstracts of the 56th Annual Meeting of the American Academy of Neurology; 24 April-1 May 2004; San Francisco, California. Abstract PO2.118.
53. Whetten-Goldenstein K, Sloan FA, Goldenstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler. 1998;4:419-425. (Pubitemid 28515352)
54. i3. Data assets: better data matters. A lot. Copyright 2007. Available at: www.i3global.com/DataAssets/. Accessed 1 July 2008.